DoxorubicinCyclophosphamideAntineoplastic Combined Chemotherapy ProtocolsDrug ResistanceAntibiotics, AntineoplasticEtoposideDaunorubicinLomustineLeukemia P388BleomycinVinblastineVinca AlkaloidsAntineoplastic Agents, PhytogenicP-GlycoproteinAntineoplastic AgentsMethotrexateDrug Resistance, MultipleLeukemia L1210NaphthacenesCombined Modality TherapyLymphoma, Non-HodgkinNogalamycinCell SurvivalDrug Administration ScheduleVerapamilAntibodies, Monoclonal, Murine-DerivedCytarabineDrug Resistance, NeoplasmPrednisoloneDactinomycinAsparaginaseTumor Cells, CulturedSemustineMelphalanVincristineLymphoma, Large B-Cell, DiffuseCisplatinDose-Response Relationship, DrugHodgkin DiseaseRemission InductionDacarbazineCarcinoma, Small CellRhabdomyosarcomaIfosfamideNephrosisLeukemia, ExperimentalDexamethasoneTreatment OutcomePodophyllotoxinKB CellsLeukemia, LymphoidMitoxantroneColchicineDisease-Free SurvivalDrug SynergismPrecursor Cell Lymphoblastic Leukemia-LymphomaDrug Screening Assays, AntitumorVindesineSurvival AnalysisTeniposideTime FactorsOligodendrogliomaCarubicinSurvival RateCarmustineChlorambucilMultiple MyelomaSarcoma 180LiposomesCatharanthusLymphomaSarcoma, EwingWilms TumorLung NeoplasmsMenogarilMultidrug Resistance-Associated ProteinsNeoplasm StagingCell LineCell DivisionDrug CarriersLeukopeniaMesnaMitomycinsPrognosisMitomycinNeoplasm TransplantationCell Line, TumorPaclitaxelAclarubicinFluorouracilAminoacridinesNimustineRandom AllocationLymphoma, FollicularNeoplasms, ExperimentalDrug EvaluationApoptosisKineticsBreast NeoplasmsNeuroblastoma